Clinical trials: Locally Advanced Pancreatic Cancer
Pancreatic Cancer
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
This phase II clinical trial studies the safety and effect of as second-line treatmen in local advanced or metastatic pancreatic cancer. The Gimatecan will be given every four weeks.
- Trial name
- NCT04571489
- Testing
- Gimatecan, tegafur, gimeracil and oteracil potassium, gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Lee's Pharmaceutical Limited
Pancreatic Carcinoma Metastatic, Pancreatic Ductal Adenocarcinoma
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
The purpose of this study is to ascertain whether treatment with lenalidomide or lenalidomide in combination with gemcitabine induces modulation of immune effector functions and to characterize the nature of immune functions.
- Trial name
- LENAGEM (NCT01547260)
- Testing
- Gemzar, Revlimid
- Where
- Sweden
- Volunteers
- 34 people
- Sponsor
- Maria Liljefors
Pancreatic Cancer
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study
The purpose of this study is to obtain preliminary safety and efficacy data after endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) in patients with locally advanced or unresectable pancreatic adenocarcinoma.
- Trial name
- NCT00578279
- Testing
- dehydrated alcohol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Pancreatic Cancer
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003018
- Testing
- dipyridamole, fluorouracil, leucovorin calcium
- Where
- 84 sites in United States
- Volunteers
- 54 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Cancer
CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer
Pancreatic ductal adenocarcinoma is a highly lethal cancer, and approximately 40% of patients present with non-metastatic locally advanced pancreatic cancer (LAPC) that is not suitable for surgical resection.
- Trial name
- PANCOSIL (NCT07595835)
- Testing
- CT-guided percutaneous intratumoural implantation of the OncoSil™ device
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- M.R. Meijerink
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be…
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma
- Trial name
- NCT07619313
- Testing
- Biopsy Procedure, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Cancer
BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BBR 3464 in treating patients who have locally advanced…
- Trial name
- NCT00024362
- Testing
- BBR 3464
- Where
- 9 sites in United States
- Sponsor
- Theradex
Cancer of Pancreas
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
This prospective cohort, phase II, trial is studying induction chemotherapy combination, FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation…
- Trial name
- NCT02311439
- Testing
- FOLFIRINOX + CRT
- Where
- Egypt
- Volunteers
- 1 people
- Sponsor
- Assiut University
Pancreatic Adenocarcinoma
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
Pancreatic cancer is difficult to treat, and even in a situation where an operation can be performed to remove the cancer, the disease can unfortunately come back soon afterwards.
- Trial name
- PRICKLE (NCT02124369)
- Testing
- Abraxane, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- CCTU- Cancer Theme
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery.
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
- Trial name
- NCT03891784
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Locally Advanced Pancreatic Cancer
Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.
this is a randomized controlled trial aims to compare between patients with locally advanced pancreatic cancer treated with EUS-guided injection of gemcitabine in addition to systemic chemotherapy, versus those who treated with…
- Trial name
- NCT07429643
- Testing
- endoscopic ultrasonograhy guided chemptherapy injection
- Volunteers
- 20 people
- Sponsor
- Assiut University
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Pancreatic Cancer
Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003029
- Testing
- cisplatin, fluorouracil
- Where
- 19 sites in Belgium, France and 3 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pancreatic Cancer
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
This is an open-label, non-randomized, combination study of cetuximab, gemcitabine, 5-FU, and external beam radiotherapy in patients with locally advanced, non-metastatic pancreatic cancer.
- Trial name
- NCT00424827
- Testing
- Gemcitabine/Fluorouracil with External Beam Radiation
- Volunteers
- 11 people
- Sponsor
- University of Massachusetts, Worcester
Locally Advanced Pancreatic Adenocarcinoma
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
To determine if carbon ion radiotherapy improves overall survival versus photon therapy in patients with locally advanced, unresectable pancreatic cancer
- Trial name
- CIPHER (NCT03536182)
- Testing
- Carbon Ion Radiation Therapy (CIRT), Intensity Modulated Radiation Therapy (IMRT)
- Where
- 2 sites in United States, Japan
- Sponsor
- University of Texas Southwestern Medical Center
Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy, Chemotherapy Effect
- Trial name
- NORPACT-3 (NCT06944587)
- Testing
- Chemotherapy, Radiology, Pancreatectomy
- Where
- 5 sites in Norway
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Pancreatic Neoplasms Malignant, Malignant Neoplasm of Gall Bladder Non-resectable
Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
SUMMARY PROJECT TITLE: Concurrent chemo-radiation using Tomotherapy based IMRT in locally advanced Gallbladder and Pancreatic cancers: A Phase II study SPECIFIC OBJECTIVES: Primary To assess the radiological response by dose…
- Trial name
- NCT01118897
- Testing
- Tomotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.